Insulin treatment improves islet function in type 2 diabetic Chinese hamsters

Summary:

To study whether normalization of hyperglycemia improves islet function in long-standing type 2 diabetes, hyperglycemic CHIG/Han subline of the genetic type 2 diabetic Chinese hamster (> 15 mmol/l; n = 23) were either treated with insulin implants (liberating 1 U/day) or vehicle for two weeks. Islets were isolated and incubated for 3 h in the presence of 10 mmol/l glucose with or without 0.1 mmol/l 3-isobutyl-l-methylxanthine (IBMX). Specimens were also taken for immunocytochemical analysis of insulin cells. Glucose-stimulated insulin secretion was reduced by 83% in the vehicle-treated diabetic hamsters compared to non-diabetic controls (p < 0.001). This impairment was not improved by the two-week insulin treatment. IBMX potentiated glucose-stimulated insulin secretion; this effect was markedly reduced in vehicle-treated diabetics compared to controls (p < 0.001). In fact, the linear relation between IBMX-potentiated and glucose-stimulated insulin secretion in controls was absent in islets from diabetic animals. The two week insulin treatment normalized this relation, although still the total insulin secretory response to IBMX and glucose was lower than in controls. Furthermore, the islet insulin content was significantly increased by the 2 week normalization of glucose and, finally, the severe degranulation and lowering of insulin staining in islet beta cells in diabetic animals were markedly improved by insulin treatment. The results suggest that two-weeks of normalization of glycemia in long-standing type 2 diabetes in non-obese Chinese hamster improves beta cell signaling induced by the cyclic AMP pathway in conjunction with improved islet insulin content and beta cell morphology.

Key words:

Type 2 diabetes - Chinese hamster - insulin treatment - insulin secretory capacity - islet hormones

References

• 1 Abdel-Salim S M, Guenifi A, Khan A, Larsson O, Berggren P O, Östenson C G, Efendic S. Impaired coupling of glucose signal to exocytotic machinery in diabetic GK rats. A defect ameliorated by cAMP.  Diabetes. 47 498-504 1996; 
• 2 Ahrén B. Glucagon-like peptide 1 (GLP-1) - a gut hormone of potential interest in the treatment of diabetes.  BioEssays. 20 642-651 1998; 
• 3 Clauson P, Alvarsson M, Grill V. Enhancement of B-cell secretion by blood glucose normalization in type 2 diabetes is associated with fasting C-peptide levels.  J Int Med. 241 493-500 1997; 
• 4 Dachicourt N, Serradas P, Giroix M H, Gangnerau M N, Portha B. Decreased glucose-induced cAMP and insulin release in islets of diabetic rats: reversal by IBMX, glucagon, GIP.  Am J Physiol. 271 E725-E732 1996; 
• 5 Drucker C J, Philippe J, Mojsov S, Chick W L, Habener J F. Glucagon-like peptide 1 stimulates insulin gene expression and increases cyclic AMP in a rat islet cell line.  Proc Nat Acad USA. 84 3434-3438 1987; 
• 6 Frankel B J, Schmid F G, Grodsky G M. Effect of continuous insulin infusion with an implantable minipump in the diabetic Chinese hamster.  Endocrinology. 104 1532-1539 1979; 
• 7 Garvey W, Olefsky J, Griffin J, Hamman R, Kolterman O. The effect of insulin treatment on insulin secretion and insulin action in type II diabetes mellitus.  Diabetes. 34 222-234 1985; 
• 8 Grodsky G M. Continuous insulin treatment in the Chinese hamster: a review.  Adv Exp Med Biol. 246 329-332 1988; 
• 9 Hellman B, Idahl L Å, Lernmark Å, Täljedal I B. The pancreatic β-cell recognition of insulin secretagogues: does cyclic AMP mediate the effect of glucose?.  Proc Nat Acad USA. 71 3405-3409 1974; 
• 10 Imamura T, Koffler M, Helderman J H, Prince D, Thirlby R, Imman L, Unger R H. Severe diabetes induced in subtotally depancreatized dogs by sustained hyperglycemia.  Diabetes. 37 600-609 1988; 
• 11 Ishida K, Mizuno A, Sano T, Noma Y, Shima K. Effects of timely insulin administration on pancreatic B-cells of Otsuka-Long Evans-Tokushima-Fatty (OLETF) strain rats.  Horm Metab Res. 27 398-402 1995; 
• 12 Kahn S E, Prigeon R L, McCulloch D, Boyko E J, Bergman R N, Schwartz M W, Neifing J L, Ward W K, Beard J C, Palmer J P, Porte D. Quantification of the relationship between insulin sensitivity and beta-cell function in human subjects. Evidence for a hyperbolic function.  Diabetes. 42 1663-1672 1993; 
• 13 Kajimoto Y, Matsuoka T, Kaneto H, Watada H, Fujitani Y, Kishimoto M, Sakamoto K, Matsuhisa M, Kawamori R, Yamasaki Y, Hori M. Induction of glycation suppresses glucokinase gene expression in HIT-T15 cells.  Diabetologia. 42 1417-1424 1999; 
• 14 Kessler J, Hehmke B, Klöting I, Kohnert K D. Relationship between the histopathology of the endocrine-exocrine pancreas parenchyma and beta-cell function in the Chinese hamster CHIG/Han subline.  Pancreas. 18 89-97 1999; 
• 15 Klöting I, Sickel E, Vogt L, Kohnert K D. CHIG/Han hamsters: an animal model for diabetes research. In: Bunyan J (ed) Welfare and Science, Proc 5th Symp Fed Eur Lab Animal Sci Ass 8-11 June 1993 Royal Soc med Press, London 190-194 1994
• 16 Kohnert K D, Hehmke B, Besch W, Keßler J, Klöting I. Impaired β-cell function in the Chinese hamster CHIG/Han subline.  Exp Clin Endocrinol. 103 66-70 1995; 
• 17 Kohnert K D, Myrsén Axcrona U, Hehmke B, Klöting I, Sundler F, Ahrén B. Islet abnormalities associated with impaired insulin secretion in type 2 diabetes in the Chinese hamster.  Regul Pept. 82 71-79 1999; 
• 18 Kohnert K D, Schröder D, Hemke B, Keßler J, Klöting I. GLUT-2 Expression und Betazellfunktion in der spontandiabetischen BB-Ratte und im Chinesischen CHIG-Hamster.  Diab Stoffw. 4 170 1995; 
• 19 Kohnert K D, Wilke B, Schmidt S, Schäfer H, Reiher K, Hahn von Dorsche H. Dietary effects on (pro)insulin biosynthesis and insulin-degrading activity in islets from sand rats.  Mol Cell Endocrinol. 43 95-103 1985; 
• 20 Kohnert K D, Wohlrab F, Hahn H J, Cossel L. Glucose transporter isoform (GLUT) 2 expression in beta cells of long-term syngeneic islet grafts.  Acta Diabetol. 34 301-304 1997; 
• 21 Kohnert K D, Ziegler B, Fält K, Odselius R, Ziegler M, Falkmer S. Biochemical, immunohistochemical and ultrastructural studies of the alteration of pancreatic beta cells resulting from the combined effects of complete Freund's adjuvant and non-diabetogenic doses of streptozotocin.  Exp Clin Endicrinol. 89 259-268 1987; 
• 22 Kosaka K, Kuzuya T, Akanuma Y, Hagura R. Increase in the insulin response after treatment of overt maturity-onset diabetes is independent of the treatment.  Diabetologia. 18 23-28 1980; 
• 23 Larsson H, Ahrén B. Failure to adequately adapt reduced insulin sensitivity with increased insulin secretion in women with impaired glucose tolerance.  Diabetologia. 39 1099-1107 1996; 
• 24 Larsson H, Ahrén B. Glucose intolerance is predicted by low insulin secretion and high glucagon secretion: outcome of a prospective study in postmenopausal Caucasian women.  Diabetologia. 43 194-202 2000; 
• 25 Lillioja S, Mott D, Spraul M, Ferraro R, Foley J E, Ravussin E, Knowler W C, Bennett P H, Bogardus C. Insulin resistance and insulin secretory dysfunction as precursors of non-insulin-dependent diabetes mellitus. Prospective studies of Pima Indians.  N Engl J Med. 329 1988-1992 1993; 
• 26 Lindström P, Sehlin J, Frankel B J. Glucose-stimulated elevation of cytoplasmic calcium is defective in the diabetic Chinese hamster islet B cell.  Eur J Endocrinol. 134 617-625 1996; 
• 27 Rabinovitch A, Renold A E, Cerasi E. Decreased cyclic AMP and insulin response to glucose in pancreatic islets of diabetic Chinese hamsters.  Diabetologia. 12 581-587 1967; 
• 28 Rosenberg L, Duguid W P, Brown R A, Vinik A I. Induction of nesidioblastosis will reverse diabetes in Syrian golden hamster.  Diabetes. 37 334-441 1988; 
• 29 Rosetti L. Glucose toxicity: the implications of hyperglycemia in the pathophysiology of diabetes mellitus.  Clin Invest Med. 18 255-260 1995; 
• 30 Simonsson E, Ahrén B. Potentiated β-cell response to non-glucose stimuli in insulin resistant C57BL/6J mice.  Eur J Pharmacol. 350 243-250 1998; 
• 31 Weir G, Clore E, Zmachinski C, Bonner-Weir S. Islet secretion in a new experimental model for non-insulin-dependent diabetes.  Diabetes. 30 590-595 1981; 
• 32 Yki-Järvinen H, Nikkilä E, Helve E, Taskinen M R. Clinical benefits and mechanisms of sustained response to intermittent insulin therapy in type 2 diabetic patients with secondary drug failure.  Am J Med. 84 185-192 1988;